The SOLAR-1 trial: alpelisib prolongs progression free survival in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients
1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer patients who have a mutated ...